ARCHIVES

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

Seffrin; First Year ACS Shows “Simple Problems Aren’t”

August 6, 1993

Schepartz New DCT Deputy Director; DeVita To Continue As Clinical Director

September 3, 1976

Antibody Targeting PD-L1 Shows Fast Tumor Shrinkage

May 31, 2013

“Over-Regulation” Threatens Health Care, Thompson Says.

June 15, 2001

High-Priority Radiation Therapy Research Projects Approved By DCT Board of Counselors

March 26, 1976

Medenica’s Claims Of Association On CV, Brochures, Challenged By Some Institutions

April 30, 1993